LONDON (Reuters) - British pharmaceutical group GlaxoSmithKline Plc said vercirnon, a drug it was developing to treat Crohn's disease and licensed from ChemoCentryx, had failed in a late-stage clinical trial. The medicine, which GSK licensed from the California-based company in 2010, did not improve the incidence of adverse events in patients when measured against a placebo, GSK said on Friday, and there was a trend for overall adverse events to increase as dosage levels increased. The trial failure wiped as much as $242 million, or nearly half, from ChemoCentryx's value. ...
via Health News Headlines - Yahoo! News http://news.yahoo.com/gsks-crohns-disease-treatment-fails-phase-iii-trial-144635108.html
No comments:
Post a Comment